2026 · 2nd Quarter (Apr 1 - June 30)

NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Filed by NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD).

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: Not reported
Expenses: $50,000.00
Registrant: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)
Filing UUID: 90378ea6-3a06-4b1a-b413-9f6b3e61343c
Termination date: Not reported

Expense method: B

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations.

HCR · Health Issues

Rare Disease Initiatives. Newborn Screening. Genetic Testing Access. Medical Nutrition Equity Act. Medical Foods and Formulas Act. Orphan Drug Act.

MMM · Medicare/Medicaid

Medicare / Medicaid issues impacting patients with rare diseases.

PHA · Pharmacy

Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.